跳转至内容
Merck
CN

主要文件

查看所有文档

160415

3-(2-吡啶基)-5,6-二苯基-1,2,4-三嗪

≥99%

别名:

5,6-二苯基-3-(2-吡啶基)-1,2,4-三嗪, PDT

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C20H14N4
化学文摘社编号:
1046-56-6
分子量:
310.35
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
24849870
EC Number:
213-878-7
Beilstein/REAXYS Number:
542151
MDL number:
MFCD00006462
Assay:
≥99%
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Quality Level

100

assay

≥99%

mp

191-193 °C (lit.)

functional group

phenyl

SMILES string

c1ccc(cc1)-c2nnc(nc2-c3ccccc3)-c4ccccn4

InChI

1S/C20H14N4/c1-3-9-15(10-4-1)18-19(16-11-5-2-6-12-16)23-24-20(22-18)17-13-7-8-14-21-17/h1-14H

InChI key

OTMYLOBWDNFTLO-UHFFFAOYSA-N

General description

3-（2-吡啶基）-5,6-二苯基-1,2,4-三嗪（PDT）与高氯酸铜（II）在乙醇中反应，可生成[Cu（PDT）2（CLO4）2]。

Application

在分光光度法测定酸和酸性溶液中的铁的过程中，使用3-（2-吡啶基）-5,6-二苯基-1,2,4-三嗪作为显色提取试剂。 它也被用作HPLC方法中的柱前衍生试剂，从而通过UV吸光度对Fe（II）进行测定。

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
WXBF7848V
WXBF6138V
WXBF2048V
WXBF0785V
WXBD8081V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Nikolay Polyakov et al.
Antioxidants & redox signaling, 28(15), 1394-1403 (2017-11-23)
Chemotherapy is currently the principal method for treating many malignancies. Thus, the development of improved antitumor drugs with enhanced efficacy and selectivity remains a high priority. Recent Advances: Anthracycline antibiotics (AAs), for example, doxorubicin, daunomycin, and mitomycin C, belong to
Sungsoon Hwang et al.
Retina (Philadelphia, Pa.), 39(6), 1117-1124 (2018-03-09)
To report the clinical outcomes of reduced-fluence photodynamic therapy (PDT) for symptomatic subfoveal retinal pigment epithelial detachment (RPED) in central serous chorioretinopathy and identify prognostic factors affecting treatment outcome. This retrospective interventional study included 35 eyes of 35 patients with
Yvonne H W Derks et al.
Theranostics, 11(4), 1527-1541 (2021-01-08)
Incomplete resection of prostate cancer (PCa) occurs in 15%-50% of PCa patients. Disease recurrence negatively impacts oncological outcome. The use of radio-, fluorescent-, or photosensitizer-labeled ligands to target the prostate-specific membrane antigen (PSMA) has become a well-established method for the
查看所有相关文献

全球贸易项目编号

货号GTIN
160415-5G04061838745521